T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced human breast carcinoma.
T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced human breast carcinoma.
复制标题
DOI：
10.1089/cbr.1994.9.7
复制
发表时间：
1994
期刊：
影响因子：
--
通讯作者：
Georg F. Springer;P. Desai;H. Tegtmeyer;Sheila C. Carlstedt;Edward F. Scanlon
中科院分区：
文献类型：
--
作者：
Georg F. Springer;P. Desai;H. Tegtmeyer;Sheila C. Carlstedt;Edward F. Scanlon
近20年来，我们使用T/Tn抗原疫苗进行安全、特异、有效、长期的皮内接种，以防止晚期乳腺癌的复发。治疗是无限期的。所有18名接受治疗的乳腺癌患者，pTNM IV（6）、III（6）和II（6）期，术后存活> 5年; 10名存活> 10至> 18年;在后者中，各有3名患者为III期和IV期。另外5例5年生存者尚未达到10年。我们的生存结果是偶然的概率，以NCI“1991年标准PDQ数据”作为对照，所有三个阶段加在一起：5年生存：p < 1 x 10（-8）; 10年生存：p < 1 x 10（-5）。没有不良副作用。接种区表现为迟发型超敏反应，但与PPD反应不同，有明显炎症，辅助性T淋巴细胞增加，T抑制细胞/细胞毒性细胞比值降低。
For nearly 20 yrs, we used T/Tn antigen vaccine in safe, specific, effective, long-term intradermal vaccination against recurrence of advanced breast carcinoma. Treatment is ad infinitum. All 18 breast carcinoma patients treated, pTNM Stages IV (6), III (6), and II (6), survived > 5 yrs postoperatively; 10 survived > 10 to > 18 yrs; of the latter, three patients each are Stages III and IV. Five additional 5 yr survivors have not yet reached 10 yrs. The probability that our survival results are due to chance, with NCI "1991 Standard PDQ Data" as control, for all three stages taken together is: 5-yr survival: p < 1 x 10(-8); 10-yr survival: p < 1 x 10(-5). There were no untoward side effects. The vaccination area presented as a delayed-type hypersensitivity reaction, but at variance with the PPD reaction, with significant inflammation, increase of helper T lymphocytes and decrease of the T suppressor/cytotoxic cell ratio.